SolasCure

If you haven't already, read our blog on, "Wound Bed Preparation: Addressing the Urgent Need for Effective Solutions” where we spoke with specialist nurses to gain their firsthand insights on wound bed preparation. Our discussions explored the challenges across both private and national health systems and emphasised the need for innovation and investment. Visit our website for the full piece: https://shorturl.at/rLbdU At SolasCure, we are developing Aurase Wound Gel specifically to overcome these barriers, providing relief to patients with an effective, quick, and easy-to-use treatment for use outside hospitals." #WoundCare #ChronicWounds

Last month, SolasCure travelled to Houston for the Global Incubator Programme kick-off, hosted by Texas Medical Center Innovation Factory and Innovate UK, the UK's innovation agency. The two-week schedule was packed with fascinating sessions and networking across the TMC, aimed at sharing knowledge and facilitating market entry for UK-based healthcare start-ups in one of the foremost medical clusters in the US. We are proud to be one of 16 companies in the 2024 cohort, selected to champion the huge collective potential of UK innovation in the US. We've been inspired and impressed by the innovative technologies which our cohort peers are developing across the biotech, medical devices and digital health sectors. The tremendous support and network the programme provides, in conjunction with the community of other exciting companies in our cohort, offers an invaluable launch pad from which each company can navigate the world's largest medical cluster. At SolasCure we have already benefited greatly and look forward to the development of our US market entry strategy and network over the next 6 months with our ongoing participation in this fantastic programme! #TMCUKBiobridge #InnovationAccelerator #HealthcareInnovation #WoundCare

Last month, SolasCure travelled to Houston for the Global Incubator Programme kick-off, hosted by Texas Medical Center Innovation Factory and Innovate UK, the UK's innovation agency. The two-week schedule was packed with fascinating sessions and networking across the TMC, aimed at sharing knowledge and facilitating market entry for UK-based healthcare start-ups in one of the foremost medical clusters in the US. We are proud to be one of 16 companies in the 2024 cohort, selected to champion the huge collective potential of UK innovation in the US. We've been inspired and impressed by the innovative technologies which our cohort peers are developing across the biotech, medical devices and digital health sectors. The tremendous support and network the programme provides, in conjunction with the community of other exciting companies in our cohort, offers an invaluable launch pad from which each company can navigate the world's largest medical cluster. At SolasCure we have already benefited greatly and look forward to the development of our US market entry strategy and network over the next 6 months with our ongoing participation in this fantastic programme! #TMCUKBiobridge #InnovationAccelerator #HealthcareInnovation #WoundCare

“We are doing the same now as we were 20 years ago.” Chronic wounds are an urgent, global problem, lacking effective solutions. While hospitals and specialised clinics often have the most advanced and effective means of treating these wounds, such methods are typically ill-suited for use outside of a hospital where most wound care treatment is carried out by community nurses. We spoke with specialist nurses to gain their firsthand insights on wound bed preparation, exploring the challenges across both private and national health systems, and the need for innovation and investment. Read the full piece on our website: https://shorturl.at/rLbdU At SolasCure, we are developing Aurase Wound Gel specifically to overcome these barriers, providing relief to patients with an effective, quick, and easy-to-use treatment for use outside hospitals. Home Wound Care #WoundCare #ChronicWounds

📃 Published in Journal of Wound Care (JWC), an international consensus document aims to provide updated guidance on the principles and techniques of #debridement.   It highlights the critical importance of #wound debridement for #chronicwounds to heal and describes a standardised approach to debridement that can be applied across different populations, introducing the concept of integrated debridement throughout the #healing period.   The primary aim of debridement is to remove #microbial and non-microbial wound components, including #biofilm, devitalised tissue, cytokines, and proteases. It is vital that all wounds are regularly debrided, unless contraindicated, as this removes barriers that delay or stall healing. While there are many approaches to debridement, these vary in efficacy, resource-intensiveness, and pain.    At the heart of SolasCure's mission to improve the lives of patients suffering from chronic wounds, is Aurase Wound Gel — an easy-to-use enzymatic debrider with demonstrated ability to remove non-viable tissue, strong local and systemic safety profile, and no added pain burden on application. Aurase Wound Gel also addresses moisture imbalance, reduces risk of infection, and promotes development of granulation tissue at all stages of the wound healing journey. Read the full consensus document ➡ https://rb.gy/ezwmrt 

A month on from the inaugural Driving Innovation in Wound Care Summit, created to address barriers to care and patient-centered solutions, it is fantastic to see evidence of the event's success.   The event, hosted by HMP Global’s Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) partnered with the Wound Care Collaborative Community, comprised over 100 participants including representatives from the FDA, leading #clinicians, #researchers, industry, and #healthcare systems.    Discussions focused on disrupting the barriers to innovation with evidence and collaborations; generating and reporting evidence; real-world evidence in FDA and payer decision-making; and defining standard of care in #woundcare #clinicaltrials and clinical practice — all critical to ensuring future innovation and patient-centered solutions for the field of wound care.   A great summary of the event can be found here ➡ https://rb.gy/ezzboi 

A much-needed qualitative study demonstrated the profound impact of chronic wound-associated pain on individuals' quality of life and daily functioning. Despite its significance, there is limited research on how people with chronic wounds perceive and manage pain. Thirteen interviews were conducted to explore these experiences, revealing two main themes. The first theme centred on participants' characterisation of pain and its impact on daily life, with many feeling functionally impaired. The second theme discussed coping strategies, particularly during dressing changes, emphasising the important role of healthcare professionals and family support networks while acknowledging the burden it places on everyone involved. The paper concludes by noting that coping with pain is exhausting and contributes to poorer quality of life, with patients expressing the need for further research on dressings rather than drugs to manage pain. Improving patients’ quality of life is a core part of our mission at SolasCure and, with Aurase Wound Gel, we aim to deliver a gentle, easy-to-use approach during dressing changes that aims to minimise additional pain. Patients should not have to accept living with chronic wound-associated pain. Read the full paper in the Society of Tissue Viability’s Journal of Tissue Viability: https://rb.gy/xypjjs #ChronicWounds #WoundCare #Hydrogel

An article published in the Nursing Times impresses the importance of holistic wound assessment and the involvement of an interprofessional team in chronic wound treatment, as well as addressing all four pillars of the TIME paradigm in order for a wound to heal: ➡ T – Tissue management (Debridement); the removal of non-viable tissue  ➡ I – Infection and inflammation management ➡ M – Moisture Balance, including the management of exudate ➡ E – Edge of wound (Epithelialization); promoting the growth of new tissue at the wound edges to facilitate closure Debridement is the crucial first step but carries varying levels of efficacy depending on the method used. Effective debridement proves challenging with current methods, often either slow and ineffective (e.g., hydrogels) or rapid but resource-intensive and/or painful (e.g., surgery, waterjets). This clearly demonstrates a need for a single, safe, and easy to use debridement solution that targets all four TIME pillars and all stages of the wound healing journey; a need that we aim to meet with our investigational product, Aurase Wound Gel. Read the full article here: https://rb.gy/pn1z0e #ChronicWounds #WoundCare #Debridement #WoundHealing

We are proud to announce that we have been selected as one of 16 healthcare companies to participate in Innovate UK’s Global Incubator Programme in Houston, delivered in partnership with the Texas Medical Center, the largest medical complex in the world.   Building on the recent European Innovation Council’s Accelerator Grant and Innovate UK Biomedical Catalyst Grant, the programme will support the future entry of Aurase Wound Gel, our first investigational product for the treatment of chronic wounds, into the US market.   Our CEO, Lee Harle, comments:   "It is a real boost to our journey at SolasCure to be selected for this Global Incubator Programme, continuing the momentum from our recent EIC Accelerator and the BMC grant wins. This represents another key piece of industry validation and recognition by TMC/TMC-Innovation, global leaders in medical innovation, that SolasCure has the potential to address a huge unmet need."   Read the full press release here: https://shorturl.at/MJTOY   #WoundCare #ChronicWounds

Last week, our team were in Orlando for the Symposium on Advanced Wound Care. As the week comes to end, it is time to reflect on the insights gained and connections made during those eventful few days. The poster, ‘First Clinical Evaluation of the Safety and Efficacy of Tarumase for the Debridement of Venous Leg Ulcers’, discussed results from the first-in-human study of a new enzymatic wound debridement product containing tarumase. 💬 Our CEO, Lee Harle, says: "It’s quite something to see wound care experts from all over the world come together to learn and share the latest data and innovations at SAWC Spring. Our takeaways for SolasCure are best summed up by the key message from the excellent Wound Care Collaborative Community day, together with the FDA: We need more truly breakthrough innovations for wounds so that we can move on from wound ‘care’ to true wound ‘therapy,’ backed by solid evidence and thus investment. This mission is what gets us up each day here at SolasCure." If you missed us at the event but want to learn more about how SolasCure is transforming wound care with Aurase Wound Gel, please visit our website ➡ https://rb.gy/dbv3g9 #SAWC #WoundCare #Hydrogel #HealthTech HMP Global Andy Weymann David Goldsmith David Fairlamb